Cargando…

Daclatasvir: potential role in hepatitis C

Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma. It has been a tremendous burden on global health care systems. With the advent of a number of new direct-acting and host-targeting antiviral agents, current interferon-α- and...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lee, Choongho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804593/ https://www.ncbi.nlm.nih.gov/pubmed/24204123 http://dx.doi.org/10.2147/DDDT.S40310

Ejemplares similares

Daclatasvir: potential role in hepatitis C [Corrigendum]
Publicado: (2014)

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
por: Gamal, Nesrine, et al.
Publicado: (2016)

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
por: Manolakopoulos, Spilios, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
por: Hua, Rui, et al.
Publicado: (2023)

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir
por: Sugiura, Ayumi, et al.
Publicado: (2017)

Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi
por: Butt, Nazish, et al.
Publicado: (2021)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol, Stanislas, et al.
Publicado: (2016)

A Review of Daclatasvir Drug–Drug Interactions
por: Garimella, Tushar, et al.
Publicado: (2016)

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019)

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease
por: Young, Jim, et al.
Publicado: (2017)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
por: Meanwell, Nicholas A., et al.
Publicado: (2018)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir
por: Zhang, Huijun, et al.
Publicado: (2022)

Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)

Interaction of Hepatitis C Virus Core Protein with Janus Kinase Is Required for Efficient Production of Infectious Viruses
por: Lee, Choongho
Publicado: (2013)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
por: Kawakubo, Megumi, et al.
Publicado: (2018)

Daclatasvir and asunaprevir improves health‐related quality of life in Japanese patients infected with hepatitis C virus
por: Ikeda, Hiroki, et al.
Publicado: (2018)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge
por: Lee, Choongho
Publicado: (2019)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019)

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
por: Zhou, Nannan, et al.
Publicado: (2016)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q7k5mntj398s7k97c1vsq8p4cm